Drugs / Post-transfection F19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00350337 | Apr 2006 → Jun 2007 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Post-transfection F19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00350337 ↗ |
| Known as | Dengue tetravalent Vaccine F19 Post transfection | “Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection” NCT00350337 ↗ |
| Modality | Vaccine | “Live Attenuated Tetravalent Dengue Vaccine” NCT00350337 ↗ |
| Route | Subcutaneous | “administered at 0 and 6 months via subcutaneous injection” NCT00350337 ↗ |